| Literature DB >> 29075349 |
Abstract
Urolithiasis is a significant social and financial problem. According to contemporary literature data, 1-5% of the global population suffers from urolithiasis. The prevalence of this disease is about 10% of the population of the Republic of Moldova. Scientific and practical researches in the field of urology, and especially those devoted to renal lithiasis, focus on the diagnosis and treatment process, giving little importance to the cause of formation, metabolic disturbances, and especially to prophylaxis and metaphylaxis of the disease recurrence. However, the impact of this disease may be diminished by specialized or general metaphylaxis treatment. The article presents results of the analysis of different methods of metaphylaxis of recurrent urolithiasis. The implementation of metaphylaxis measures significantly reduces the rate and risk of recurrence in patients with recurrent urolithiasis. Specialized metaphylaxis treatment reduces the risk of lithiasis recurrence 5 times and general metaphylaxis - 2 times compared to the lack of metaphylaxis, which requires this treatment to prevent the recurrence of urolithiasis.Entities:
Keywords: metaphylaxis; recurrence prevention; specialized or general metaphylaxis treatment; urolithiasis
Mesh:
Year: 2017 PMID: 29075349 PMCID: PMC5652268
Source DB: PubMed Journal: J Med Life ISSN: 1844-122X
Distribution of patients by gender and age
| Number of patients | ||||||
| Patients’ age | Males | Females | Total | |||
| n | % | n | % | n | % | |
| 18-30 years old | 6 | 3,8% | 11 | 6,9% | 17 | 10,6% |
| 31-60 years old | 38 | 23,7% | 67 | 41,8% | 105 | 65,6% |
| Over 60 years old | 10 | 6,3% | 28 | 17,5% | 38 | 23,8% |
| Total | 54 | 33,8% | 106 | 66,2% | 160 | 100% |
Patients’ distribution in research groups
| Parameters | Group I | Group II | Group III | Total | Pearson’s χ2 (DF) | p | |
| Gender | Males | 19 | 14 | 21 | 54 | 2,631 (2) | 0,268 |
| Females | 39 | 38 | 29 | 106 | |||
| Total | 58 | 52 | 50 | 160 | |||
| Age (years) | 18-30 | 6 | 6 | 5 | 17 | 0,259 (4) | 0,992 |
| 31-60 | 39 | 35 | 31 | 105 | |||
| Over 60 | 13 | 11 | 14 | 38 | |||
| Total | 58 | 52 | 50 | 160 | |||
| Treatment applied | ESWL | 21 | 21 | 20 | 62 | 0,259 (4) | 0,992 |
| PLT | 25 | 21 | 20 | 66 | |||
| URS | 12 | 10 | 10 | 32 | |||
| Total | 58 | 52 | 50 | 160 | |||
Rate of recurrence of urolithiasis in investigated group
| Group | Recurrent | Non recurrent | Total | χ2 | p |
| n (%) | n (%) | ||||
| Group I | 7 (12,1%) | 51 (87,9%) | 58 | 14,2 | 0,0008 |
| Group II | 13 (25,0%) | 39 (75,0%) | 52 | ||
| Group III | 22 (44,0%) | 28 (56,0%) | 50 | ||
| Total | 42 (26,3%) | 118 (73,7%) | 160 |
Relative risk of urolithiasis recurrence in studied groups
| Group | RR | CI 95% | χ2 | p |
| Group I (n=58) | 0,22 | 0,09 – 0,51 | 13,9 | 0,0001 |
| Group II (n=52) | 0,495 | 0,24 – 0,98 | 4,08 | 0,044 |
| Group III (n=50) | - | - | - | - |
Average time until stone recurrence
| Groups | Mean (months) | Standard Deviation | 95% Confidence Interval | Log-rank test (Mantel-Cox) | P | |
| Upper limit | Lower limit | |||||
| Group I | 34,379 | 0,648 | 33,110 | 35,649 | 15,067 | 0,0001 |
| Group II | 31,846 | 1,145 | 29,602 | 34,090 | ||
| Group III | 27,860 | 1,538 | 24,845 | 30,875 | ||
| Total | 31,519 | 0,685 | 30,176 | 32,862 | ||
Results of pairs comparisons to recurrence rate between the investigated groups
| Pairs comparisons | Group I | Group II | Group III | ||||
| χ2 | p | χ2 | p | χ2 | p | ||
| Log Rank test (Mantel-Cox) | Group I | 3,261 | 0,071 | 14,965 | 0,000 | ||
| Group II | 3,261 | 0,071 | 4,261 | 0,039 | |||
| Group III | 14,965 | 0,000 | 4,261 | 0,039 |